Drug resistance and new cancer treatments : C. Gongora


One of the main causes of failure in cancer treatment is the development of drug resistance by cancer cells. In the past decades, new drugs (particularly the so-called targeted therapies, such as monoclonal antibodies or tyrosine kinase inhibitors and immune checkpoint inhibitors) have been developed to bypass therapeutic failure in cancer treatment. However, the assessment of these targeted therapies, either alone or in combination with standard cytotoxic agents, in clinical trials shows that, although some are efficient and have been subsequently approved for routine clinical use, many of them are not. Indeed, most solid tumors display huge genomic complexity and therefore multiple pathways or networks need to be targeted to affect tumor survival. Furthermore, the assessment of the efficacy of a new drug can be complicated by inter- and intra-patient pharmacokinetic variations that can result in unpredictable toxicity and variable anticancer effects.

The research project of this group focus on optimizing drug therapy in solid tumor models. The main axes of our research project are: a) the identification of innovative targets, b) the development of treatments to overcome drug resistance, c) the comprehension of drug responses and d) the identification of biomarkers of cancer development and drug resistance.



Combes E, Andrade A, Tosi D, Michaud H-A, Coquel F, Desigaud D, Jarlier M, Coquelle A, Pasero P, Bonnefoy N, Martineau P, Del Rio M, Beijersbergen R, Vezzio-Vie N Inhibition of Ataxia-Telangiectasia Mutated and RAD3-related (ATR) overcomes oxaliplatin resistance and promotes anti-tumor immunity in colorectal cancer. Cancer Res.. Apr 15, 2019. doi:10.1158/0008-5472.CAN-18-2807

Cherradi S, Martineau P, Gongora C, Del Rio M Claudin gene expression profiles and clinical value in colorectal tumors classified according to their molecular subtype. Cancer Manag Res. 2019;11. doi:10.2147/CMAR.S188192

Corvaglia V, Carbajo D, Prabhakaran P, Ziach K, Mandal P, Santos V, Legeay C, Vogel R, Parissi V, Pourquier P, Huc I Carboxylate-functionalized foldamer inhibitors of HIV-1 integrase and Topoisomerase 1: artificial analogues of DNA mimic proteins. Nucleic Acids Res.. May 10, 2019. doi:10.1093/nar/gkz352

Ziach K, Chollet C, Parissi V, Prabhakaran P, Marchivie M, Corvaglia V, Bose P, Laxmi-Reddy K, Godde F, Schmitter J-M, Chaignepain S, Pourquier P, Huc I Single helically folded aromatic oligoamides that mimic the charge surface of double-stranded B-DNA. Nat Chem. 2018;10(5):511-518. doi:10.1038/s41557-018-0018-7

Cherradi S, Ayrolles-Torro A, Vezzo-Vié N, Gueguinou N, Denis V, Combes E, Busson M, Canterel-Thouennon L, Mollevi C, Pugnière M, Bibeau F, Ychou M, Martineau P, Gongora C, Del Rio M Antibody targeting of claudin-1 as a potential colorectal cancer therapy. J. Exp. Clin. Cancer Res.. 2017;36(1):89. doi:10.1186/s13046-017-0558-5


Team Leader  : Céline Gongora

Institut de Recherche en
Cancérologie de Montpellier
Campus Val d’Aurelle
34298 Montpellier cedex 5

Tél. : 33 (0)4 67 61 37 45
Fax : 33 (0)4 67 61 37 87

Discover the team


partners / funding


© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés